The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and ...

Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one ...

Azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...